Kirsten E. Coleman

662 citations

14 papers · 333 indexed · h-index 10

Co-authors: Barry J. Byrne Manuela Corti Roland W. Herzog Barbara K. Smith David D. Fuller Thomas J. Conlon İbrahim Sacit Tuna Saleem Islam
Topics: Virus-based gene therapy research (10 papers)CAR-T cell therapy research (4 papers)Retinal Development and Disorders (2 papers)
Cited by: Genetics Physiology
Journals: Journal of Clinical Investigation Molecular Therapy Human Gene Therapy
Partner nations: United States India France

In The Last Decade

Kirsten E. Coleman

11 papers receiving 327 citations

Peers

Countries citing papers authored by Kirsten E. Coleman

Since Specialization

Citations

This map shows the geographic impact of Kirsten E. Coleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirsten E. Coleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirsten E. Coleman more than expected).

Fields of papers citing papers by Kirsten E. Coleman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirsten E. Coleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirsten E. Coleman. The network helps show where Kirsten E. Coleman may publish in the future.

Co-authorship network of co-authors of Kirsten E. Coleman

This figure shows the co-authorship network connecting the top 25 collaborators of Kirsten E. Coleman. A scholar is included among the top collaborators of Kirsten E. Coleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirsten E. Coleman. Kirsten E. Coleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Enhancing AAV9-UFμDys1 Gene Therapy Efficacy Through Immunosuppression in Mice with Pre-Existing Immunity and Enabling Redosing Strategies for Duchenne Muscular Dystrophy 2025 ·Human Gene Therapy ·Madhurima Saha,(unknown),Craig Meyers,Kirsten E. Coleman,(unknown),(unknown),Moanaro Biswas,Roland W. Herzog,Barry J. Byrne,Manuela Corti	0
2	Quantification and comparison of anti-AAV9 and anti-AAVrh74 antibodies in plasma and human milk: Implications for AAV-based gene therapy candidacy 2025 ·Journal of Neuromuscular Diseases ·Carmen Leon‐Astudillo,Kirsten E. Coleman,Stephanie Salabarria,(unknown),(unknown),Joseph Larkin,Josef Neu,Manuela Corti,Barry J. Byrne	0
3	Total and Neutralizing Antibody Seroprevalence of Hepatotropic Adeno-Associated Virus Among Healthy and Hemophilia A or B Population from India 2025 ·Human Gene Therapy ·Hubert Darius J. Daniel,(unknown),Rajesh Kannangai,Sanjay Kumar,Kavitha M. Lakshmi,(unknown),(unknown),(unknown),(unknown),Aby Abraham,Kirsten E. Coleman,Arun Srivastava,Alok Srivastava,Asha Mary Abraham	0
4	Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies 2023 ·Journal of Clinical Investigation ·(unknown),Manuela Corti,Kirsten E. Coleman,(unknown),Julie Berthy,Precilla D’Souza,Cynthia J. Tifft,Roland W. Herzog,Melissa E. Elder,Lawrence R. Shoemaker,Carmen Leon‐Astudillo,(unknown),David H. Kirn,Jonathan D. Schwartz,Barry J. Byrne	67
5	A clinically viable approach to restoring visual function using optogenetic gene therapy 2023 ·Molecular Therapy — Methods & Clinical Development ·(unknown),Suresh Viswanáthan,Scott E. Brodie,Wen‐Tao Deng,Kirsten E. Coleman,William W. Hauswirth,Sheila Nirenberg	15
6	Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation 2023 ·Molecular Therapy — Methods & Clinical Development ·Manuela Corti,Barry J. Byrne,Dominic J. Gessler,Grace Thompson,(unknown),Jenna Lammers,Kirsten E. Coleman,(unknown),Melissa E. Elder,Maria L. Escolar,İbrahim Sacit Tuna,Clementina Mesaros,Gary Kleiner,Deborah Barbouth,Heather Gray‐Edwards,Nathalie Clément,Brian Cleaver,Guangping Gao	15
7	Age‐stratified adeno‐associated virus serotype 3 neutralizing and total antibody prevalence in hemophilia A patients from India 2022 ·Journal of Medical Virology ·Hubert Darius J. Daniel,Sanjay Kumar,Rajesh Kannangai,(unknown),(unknown),Aby Abraham,Kavitha M. Lakshmi,Mavis Agbandje‐McKenna,Kirsten E. Coleman,Arun Srivastava,Alok Srivastava,Asha Mary Abraham	4
8	Voluntary wheel running complements microdystrophin gene therapy to improve muscle function in mdx mice 2021 ·Molecular Therapy — Methods & Clinical Development ·(unknown),(unknown),(unknown),Adele K. Addington,Haiyan Zhang,Justin B. Perry,Ryan P. McMillan,Michael W. Lawlor,(unknown),(unknown),(unknown),Kirsten E. Coleman,(unknown),David L. Mack,David A. Brown,Carl Morris,J. Patrick Gonzalez,Robert W. Grange	11
9	A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system 2021 ·Molecular Therapy ·Oleksandr Kondratov,Liudmyla Kondratova,Ronald J. Mandel,Kirsten E. Coleman,Michael A. Savage,Heather Gray‐Edwards,Timothy J. Ness,(unknown),Robert D. Bell,Joseph E. Rabinowitz,Paul D. Gamlin,Sergei Zolotukhin	39
10	Prevalence of Adeno-Associated Virus 3 Capsid Binding and Neutralizing Antibodies in Healthy and Hemophilia B Individuals from India 2020 ·Human Gene Therapy ·Hubert Darius J. Daniel,Sanjay Kumar,Rajesh Kannangai,Kavitha M. Lakshmi,Mavis Agbandje‐McKenna,Kirsten E. Coleman,Arun Srivastava,Alok Srivastava,Asha Mary Abraham	15
11	Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy 2019 ·Annals of Translational Medicine ·Barry J. Byrne,David D. Fuller,Barbara K. Smith,Nathalie Clément,Kirsten E. Coleman,Brian Cleaver,Lauren A. Vaught,Darin J. Falk,(unknown),Manuela Corti	38
12	Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice 2018 ·PubMed ·Chunjuan Song,Thomas J. Conlon,Wen‐Tao Deng,Kirsten E. Coleman,Ping Zhu,(unknown),(unknown),(unknown),Kari B. Green,(unknown),Alok Sharma,Adrian M. Timmers,Paulette M. Robinson,David R. Knop,William W. Hauswirth,Jeffrey D. Chulay,Mark S. Shearman,Guojie Ye	16
13	Long‐term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia 2018 ·Journal of Inherited Metabolic Disease ·Young‐Mock Lee,Thomas J. Conlon,Andrew J. Specht,Kirsten E. Coleman,Laurie M. Brown,(unknown),(unknown),Kathryn Dahlberg,David A. Weinstein	23
14	Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV- hGAA ) Gene Therapy in Children Affected by Pompe Disease 2017 ·PubMed ·Manuela Corti,(unknown),Barbara K. Smith,Lee Ann Lawson,İbrahim Sacit Tuna,Thomas J. Conlon,Kirsten E. Coleman,Saleem Islam,Roland W. Herzog,David D. Fuller,Shelley Collins,Barry J. Byrne	90

About Kirsten E. Coleman

Kirsten E. Coleman is a scholar working on Genetics, Physiology and Genetics, having authored 14 papers that have together received 333 indexed citations. Recurring topics across this work include Virus-based gene therapy research (10 papers), CAR-T cell therapy research (4 papers) and Retinal Development and Disorders (2 papers). The work is most often cited by research in Genetics (184 citations), Physiology (84 citations) and Genetics (34 citations). Kirsten E. Coleman has collaborated with scholars based in United States, India and France. Frequent co-authors include Barry J. Byrne, Manuela Corti, Roland W. Herzog, Barbara K. Smith, David D. Fuller, Thomas J. Conlon, İbrahim Sacit Tuna, Saleem Islam, Shelley Collins and Lee Ann Lawson. Their work appears in journals such as Journal of Clinical Investigation, Molecular Therapy and Human Gene Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact